Trial Profile

Second Phase 3 Clinical Trial to Evaluate VP-102 for the Treatment of Common Warts (Verruca Vulgaris)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cantharidin (Primary)
Indications Warts
Focus Registrational; Therapeutic Use
Sponsors Verrica Pharmaceuticals

Most Recent Events

13 May 2025 According to a Verrica Pharmaceuticals media release, company is working with a Japanese development and commercialization partner, Torii Pharmaceutical, to initiate this global Phase 3 program of YCANTH for the treatment of common warts.
14 Aug 2024 According to a Verrica Pharmaceuticals media release, initiation of the trial expected in 1H 2025
29 Feb 2024 According to a Verrica Pharmaceuticals media release, the Company will be seeking additional FDA feedback on its updated clinical design in the second quarter of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com